Prognostic scoring systems in malignant mesothelioma
| First author [ref.] | Subjects n | Parameter | Good prognostic group | Poor prognostic group | |
| CALGB | Herndon 40 | 337 | Performance statusAgeChest painPlatelet countLDH | Good<75 yrsAbsent<400 ×1012·L−1<500 IU·L−1 | Poor≥75 yrsPresent≥400 ×1012·L−1≥500 IU·L−1 |
| EORTC | Curran 41 | 204 | Performance statusHistological subtypeSexCertainty of diagnosisWBC count | 0EpitheloidFemaleDefinite<8.3 ×109·L−1 | 1–2NonepitheloidMalePossible≥8.3 ×109·L−1 |
| EORTC# | van Meerbeeck 42 | 250 | StageHistologyInterval since diagnosisPlatelet countHaemoglobin difference¶PainAppetite loss | I–IIEpitheloid<50 days<350 ×1012·L−1<1AbsentAbsent | III–IVNonepitheloid≥50 days≥350 ×1012·L−1>1PresentPresent |
CALGB: Cancer and Leukaemia Group B; EORTC: European Organization for Research and Treatment of Cancer; LDH: lactate dehydrogenase; WBC: white blood cell. #: performance status 0–1 was an inclusion criterion for this series; ¶: difference between actual value and 16 g·dL−1 and 14 g·dL−1 in males and females, respectively.